Symposium: Re-inventing adherence: Patient-centered approaches to drug-resistant TB and HIV treatment
The meeting will pull together researchers, public health workers, and activists to define an implementation and research agenda for drug-resistant TB and HIV treatment adherence that is centered on the unique needs of the communities most affected by these synergistic epidemics.
TB researchers, advocates and clinicians in New York––please join Columbia University, ICAP, TAG and the Stony-Wold Herbert Foundation at Columbia University on March 19 for a symposium titled "Re-inventing adherence: Patient-centered approaches to drug-resistant TB and HIV treatment".
Please visit tbhiv-colloq.org for further details and to register for the event. See agenda here.
Drug-resistant TB/HIV is a global health emergency. The development of new TB diagnostics, drugs and treatment regimens presents us with exciting opportunities to improve outcomes for patients and reduce community transmission of drug-resistant TB.
Without equally innovative approaches to patient-centered care, this opportunity to impact the epidemic may be short-lived. It is time to re-invent our understanding of adherence in drug-resistant TB/HIV to eliminate disease and the stigma associated with it by focusing our efforts and attention on affected patients and communities.
The meeting will pull together researchers, public health workers, and activists to define an implementation and research agenda for drug-resistant TB and HIV treatment adherence that is centered on the unique needs of the communities most affected by these synergistic epidemics.